About
Long acting retinal medicines
Areas of Focus
Categories
Biologics & BiopharmaceuticalBiotech
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
11
As Collaborator
0
Total Enrollment
4,207
By Phase
PHASE3: 9PHASE2/PHASE3: 1PHASE1: 1
By Status
TERMINATED: 5RECRUITING: 3COMPLETED: 2ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06990399Lead Sponsor
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
PHASE3Recruiting
150 participants
Started: Jul 30, 2025 · Completed: Jul 31, 2027
NCT06996080Lead Sponsor
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
PHASE3Recruiting
150 participants
Started: Jul 16, 2025 · Completed: Jul 31, 2027
NCT06556368Lead Sponsor
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
PHASE3Recruiting
675 participants
Started: Aug 23, 2024 · Completed: Apr 30, 2027
NCT06270836Lead Sponsor
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
PHASE3Active, not recruiting
255 participants
Started: May 1, 2024 · Completed: Jan 31, 2026
NCT05066230Lead Sponsor
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
PHASE3Terminated
253 participants
Started: Sep 7, 2021 · Completed: Aug 31, 2023
Locations (1)
Headquarters
Palo Alto, CA, United States
Map
Loading map...